Theratechnologies Extends Patent Protection For Tesamorelin In The Treatment Of HIV-Associated Lipodystrophy

Theratechnologies (TSX:TH) announced that the United States Patent and Trademark Office has issued Patent Number 7,316,997 entitled “GH Secretagogues and Uses Thereof” to Theratechnologies. This patent covers methods of treatment of HIV-associated lipodystrophy using Theratechnologies’ lead investigational new drug, tesamorelin (TH9507). The granting of this patent extends the patent protection of tesamorelin in HIV-associated lipodystrophy for eight additional years.

More: continued here

Filed under: HIV / AIDS on January 9th, 2008